Bradley Pharmaceuticals to consider alternatives, Glassman group proposal

By Lisa Kerner

Charlotte, N.C., June 4 - Bradley Pharmaceuticals, Inc.'s special committee will work with Deutsche Bank Securities to consider the company's strategic alternatives, including the proposal received last week from a group of investors led by founder, president and chief executive officer Daniel Glassman.

The group wants to acquire all of the outstanding shares of Bradley common stock and class B common stock for $21.50 per share in cash, according to a company news release.

One Equity Partners LLC provided a new cash equity commitment for the deal.

Bradley is a Fairfield, N.J.-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.